TWO CASES OF MONKEYPOX-ASSOCIATED ENCEPHALOMYELITIS — COLORADO AND THE DISTRICT OF COLUMBIA, JULY–AUGUST 2022
Two patients had confirmed systemic MPXV infections with encephalomyelitis appearing within 5 and 9 days of illness onset. The underlying pathology behind this is unclear but might represent either MPXV invasion of the CNS or a parainfectious autoimmune process triggered by systemic MPXV infection. Both patients had some clinical and radiographic features of acute disseminated encephalomyelitis (ADEM), typically a monophasic parainfectious autoimmune demyelinating disease of the CNS that primarily affects children but can also occur in adults
Clinicians and public health professionals should be aware of the range of possible clinical presentations of MPXV infections and potential treatments.
Full Access: CDC
EVEN MILD COVID TIED TO VASCULAR IMPAIRMENT
COVID-19 infection is significantly associated with chronically impaired cerebral vasoreactivity (CVR). In a small prospective study, participants who previously had COVID-19, even those with mild illness, had significantly decreased CVR compared with never-infected individuals. Results also showed cerebral blood flow (CBF) was greater in never-infected vs previously infected participants, and whole-brain CVR was lower in previously infected vs never-infected participants.
Full Access: Medscape
CHANGES IN EMERGENCY DEPARTMENT VISITS FOR CANNABIS HYPEREMESIS SYNDROME (CHS) FOLLOWING RECREATIONAL CANNABIS LEGALIZATION AND SUBSEQUENT COMMERCIALIZATION IN ONTARIO, CANADA
In this cross-sectional study including 12 866 ED visits for CHS from 8140 individuals, rates of CHS ED visits increased by 13-fold over 7.5 years. Legalization was not associated with increased CHS visits, but market commercialization, which overlapped with the COVID-19 pandemic, was. These findings suggest that commercialization of cannabis markets may be a driving factor of increased CHS ED visits in Ontario; therefore, health care practitioners should be aware of CHS symptoms and treatment.
Full Access: JAMA
CLINICAL GUIDELINES SYNOPSIS – MANAGEMENT OF HEART FAILURE
2022 American College of Cardiology (ACC)/ American Heart Association AHA/Heart Failure Society of America (HFSA). The new guidelines provide updated recommendations of medical therapy for patients with HF across the spectrum of EF. Importantly, the guidelines emphasize differences in treatment regimens, and their associated levels of evidence, within the context of the new universal definition of HF.
Full Access: JAMA